|
|
||||||||
|
|
|||||||||
|
|
Radiopharmaceutical Chemistry: Dosimetry/RadiobiologyDosimetry/Radiobiology Posters |
1 DSV/I2BM/SHFJ, CEA, Orsay, France; 2 Laboratoire de Physique Moléculaire, Institut de Physique, Metz, France; 3 Nuclear Medicine, St Antoine Hospital, Paris, France; 4 Nuclear Medicine, St Louis Hospital, Paris, France
1208
Objectives: Although 18F-FDG examinations are widely used, data are lacking on the dose to human embryo tissues in case of exposure in early pregnancy, as the intensity of embryo tissue uptake, which is essential for deriving the β+ dose, is not known. We report the case of a patient who underwent 18F-FDG PET/CT for tumour surveillance and who was later found to have been pregnant at the time of the examination (embryo age 8 weeks).
Methods: The patient received 320 MBq of 18F-FDG. Imaging started 1 hour after the injection with an unenhanced CT scan, followed by PET acquisition. PET images were used to compute the total number of β+ emissions in embryo tissues per unit of injected activity, from SUV measurements corrected for partial volume effects. A Monte Carlo track structure code was then used to derive the β+ self-dose and the β+ cross-dose from amniotic fluid. The gamma and CT doses were added to obtain the final dose received by the embryo.
Results: The mean SUV in embryo tissues was 2.7, after correction for the partial volume effect. The mean corrected SUV of amniotic fluid was 1.1. Monte Carlo simulation showed that the β+ dose to the embryo (self-dose + cross-dose from amniotic fluid) was 1.8E-2 mGy per MBq of injected 18F-FDG. Based on MIRD data for the gamma dose to the uterus, the estimated gamma photon embryo dose was 1.5E-2 mGy/MBq. Thus, the specific FDG embryo dose was 3.3E-2 mGy/MBq. The CT scan added a further 8.3 mGy.
Conclusions: The dose to the embryo is 3.3E-2 mGy per MBq of 18F-FDG. The β+ dose contributes 55% of the total dose. This value is higher than previous estimates in late non human primate pregnancies.
| ||||||||||||||||||||||||||||||||||||||